Mezigdomide, Carfilzomib, and Dexamethasone for Relapsed Myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or is not responding to treatment, and you have at least one lesion outside the bone (extramedullary disease).
- You are 18 or older and your general health level (ECOG score) is 0, 1, or 2.
- You must have measurable signs of myeloma activity, such as a certain level of M-protein in blood or urine, or free light chains in blood.
- Your kidney, liver, and blood cell counts meet minimum safety levels (doctor will check).
- You have not recently used certain medications that interfere with the study drugs, and you agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SX-682) added to a standard three-drug combination (carfilzomib, daratumumab, and dexamethasone) for people whose multiple myeloma has come back or stopped responding to previous treatment. The goal is to see if adding this drug helps control the cancer better.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
This Phase 2 trial tests iberdomide plus daratumumab, carfilzomib, and dexamethasone in people whose multiple myeloma has come back or not responded. The goal is to increase how often patients reach “MRD-negative” status, meaning very small amounts of cancer cells are not detectable, which may help improve outcomes.
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
This trial tests whether a new combination of drugs (daratumumab and teclistamab) works better than the usual treatments for multiple myeloma that has come back or stopped responding, especially in people with a high-risk form of the disease. Participants will be randomly assigned to get either the new combo or one of the standard combos.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
Hear when a new Extramedullary Disease in Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.